Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy

to related objects

Abstract: Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority accumulate in the liver or spleen after injection. Tissue‐specific mRNA delivery can be achieved through modulating LNP properties, such as tuning PEGylation or varying lipid components systematically. In this paper, a streamlined method is used for incorporating tumor‐targeting peptides into the LNPs; the programmed death ligand 1 (PD‐L1) binding peptides are conjugated to PEGylated lipids via a copper‐free click reaction, and directly incorporated into the LNP composition (Pep LNPs). Notably, Pep LNPs display robust interaction with PD‐L1 proteins, which leads to the uptake of LNPs into PD‐L1 overexpressing cancer cells both in vitro and in vivo. To evaluate anticancer immunotherapy mediated by restoring tumor suppressor, mRNA encoding phosphatase and tensin homolog (PTEN) is delivered via Pep LNPs to PTEN‐deficient triple‐negative breast cancers (TNBCs). Pep LNPs loaded with PTEN mRNA specifically promotes autophagy‐mediated immunogenic cell death in 4T1 tumors, resulting in effective anticancer immune responses. This study highlights the potential of tumor‐targeted LNPs for mRNA‐based cancer therapy.

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy ; day:23 ; month:03 ; year:2024 ; extent:15
Advanced science ; (23.03.2024) (gesamt 15)

Creator: Kim, Yelee
Choi, Jiwoong
Kim, Eun Hye
Park, Wonbeom
Jang, Hochung
Jang, Yeongji
Chi, Sung‐Gil
Kweon, Dae‐Hyuk
Lee, Kyuri
Kim, Sun Hwa
Yang, Yoosoo

DOI: 10.1002/advs.202309917

URN: urn:nbn:de:101:1-2024032413045322638763

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kim, Yelee
Choi, Jiwoong
Kim, Eun Hye
Park, Wonbeom
Jang, Hochung
Jang, Yeongji
Chi, Sung‐Gil
Kweon, Dae‐Hyuk
Lee, Kyuri
Kim, Sun Hwa
Yang, Yoosoo

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

Analyse der zellulären und löslichen Immuncheckpoint-Komponenten PD-L1 und sPD-L1 beim Nierenzellkarzinom

Related objects

Reset password